Vitamin D for glycemic control following an acute pulmonary exacerbation: A

secondary analysis of a multicenter, double-blind, randomized, placebo-

controlled trial in adults with cystic fibrosis

Alisa K. Sivapiromrat[1], William R. Hunt, MD[2], Jessica A. Alvarez PhD, RD[1], Thomas R. Ziegler

MD, MS,[1,3] and Vin Tangpricha MD, PhD[1,3]*

[1]   Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine,

7   Atlanta, GA, USA.

8 [2]   Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School

9   of Medicine, Atlanta, GA, USA.

[3]   Atlanta VA Medical Center, Decatur, GA, USA.

*   Correspondence: vin.tangpricha@emory.edu

Abstract: Individuals with cystic fibrosis (CF) often incur damage to pancreatic tissue due to a

dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein, leading to

altered chloride transport on epithelial surfaces and subsequent development of cystic fibrosis-

related diabetes (CFRD). Vitamin D deficiency has been associated with the development of

CFRD. This was a secondary analysis of a multicenter, double-blind, randomized, placebo-

controlled study in adults with CF hospitalized for an acute pulmonary exacerbation (APE),

known as the Vitamin D for the Immune System in Cystic Fibrosis (DISC) trial (NCT01426256).

This was a pre-planned secondary analysis to examine if a high-dose bolus of cholecalciferol

(vitamin D_3) can mitigate declined glucose tolerance commonly associated with an acute

pulmonary exacerbation (APE). Glycemic control was assessed by hemoglobin A1c (HbA1c)

and fasting blood glucose levels before and 12 months after the study intervention. Within 72

hours of hospital admission, participants were randomly assigned to a single dose of oral vitamin

D_3 (250,000 IU) or placebo, and subsequently, received 50,000 IU of vitamin D_3 or placebo

every other week, beginning at month 3 and ending on month 12. Forty-nine of the 91

participants in the parent study were eligible for the secondary analysis. There were no

differences in 12-month changes in HbA1c or fasting blood glucose in participants randomized

to vitamin D or placebo. A high-dose bolus of vitamin D_3 followed by maintenance vitamin D_3

supplementation did not improve glycemic control in patients with CF after an APE.

Keywords: cystic fibrosis; vitamin D; glycemic control; hospitalized adults; hyperglycemia;

acute pulmonary exacerbation

1. Introduction

Cystic fibrosis-related diabetes (CFRD) is the most common non-pulmonary co-

morbidity associated with cystic fibrosis (CF) with a prevalence of up to 40-50% of adults with

CF [1]. CF is a multi-organ disease caused by altered chloride transport on epithelial surfaces,

leading to thick mucus secretions in organs such as the lung and pancreas, resulting in chronic

infection, inflammation, and damage [2, 3]. Thickened mucosal secretions in the pancreatic ducts

can obstruct and damage pancreatic tissue, leading to CFRD [1, 4]. Destruction of exocrine

pancreatic tissue leads to fat malabsorption, resulting in undernutrition and vitamin deficiencies,

including fat-soluble vitamins like D [5-7, 8]. Destruction of endocrine pancreas tissue

contributes to disturbances in insulin secretion, and ultimately, CFRD in some individuals [1, 4].

Before CFRD onset, patients with CF experience significant pulmonary status and lung

function decline [9], and consequently, a higher risk for recurrent pulmonary exacerbations [10];

however, insulin therapy has been seen to mitigate some of the negative effects [11]. Similarly, it

has been suggested that untreated hyperglycemia has been associated with declined recovery

from acute pulmonary exacerbation (APE) [12]. Hyperglycemia increases glucose within the

airways, which allows bacteria to replicate faster, possibly contributing to an increased frequency

of pulmonary exacerbations and worsened recovery [13, 14]. Continuous glucose monitoring in a

patient with CF showed significantly higher interstitial glucose values in the week prior to a

pulmonary exacerbation, suggesting APE frequency and glucose intolerance may be associated

[14]. Therefore, improving glycemic control in patients with CF may enhance quality of life and

lower mortality.

Vitamin D deficiency has been associated with prediabetes, insulin resistance, and an

increased likelihood of developing diabetes [15-22]. Vitamin D deficiency is seen to have a

causal effect on less efficient intestinal absorption of calcium [23]. Adequate calcium absorption

may be beneficial to decrease the risk of CFRD due to its ability to stimulate insulin release to

the blood and its possible indirect effect on weight loss [24-27]. Further, in the context of CF,

vitamin D_3 (cholecalciferol) supplementation has been associated with improved insulin

secretion and decreased risk for CFRD [8, 28]. In a systematic review of seven randomized

control trials of children with obesity, four trials indicated that vitamin D supplementation had a

positive impact on glycemic control as determined by insulin levels, insulin resistance, and

fasting blood glucose [29]. Prior studies have indicated differing results, especially about optimal

vitamin D dosage and duration. A recent study in rats with type 2 diabetes (induced by a high

carbohydrate and fat diet) indicated vitamin D_3 treatment can counteract changes induced by

hyperglycemia, therefore, diminishing metabolic dysregulation seen in the diabetic state [30].

Consequently, vitamin D supplementation may improve glycemic control in patients with CF.

Following critical illness or injury, such as an APE, blood glucose levels rise in response

to metabolic effects, such as increased glucocorticoid and catecholamine hormone concentrations

as well as greater insulin resistance in peripheral tissues [31-33]. The potential mechanisms for

this acute development of insulin resistance are increased levels of suppressors of cytokine

signaling proteins, leading to less insulin receptor substrate signaling or increased circulating

free fatty acids [33]. Studies showed that hyperglycemia is highly prevalent during pulmonary

exacerbations in patients with CF [34]. Therefore, we proposed that vitamin D may have some

therapeutic effects to curb hyperglycemia and insulin resistance following an APE in adults with

CF.

To our knowledge, there have been no prior studies currently that have examined changes

in glycemic control after treatment of a high-dose bolus of vitamin D_3 supplementation following

an APE. Further, very few studies examine hyperglycemia in CF patients after an APE. A study

showed pediatric patients who were admitted for a pulmonary exacerbation of CF had

hyperglycemia that seemed to improve upon exacerbation treatment initially but had declined

glucose tolerance after extended follow-up (3.8 - 6.3 months) [34]. Studies have indicated that

poor glycemic control in adults and children with CF is associated with worsened FEV1

recovery, suggesting untreated hyperglycemia can negatively affect recovery from APEs [12, 34,

35]. Hyperglycemia has been described as a potential adjustable factor to improve recovery from

pulmonary exacerbations [34].

This study aimed to examine changes in glycemic control, quantified by changes in

hemoglobin A1c (HbA1c) and fasting blood glucose values, after administration of a high-dose

bolus of vitamin D in adults with CF after an APE. This study was a pre-planned secondary

analysis of the Vitamin D in the Immune System in Cystic Fibrosis (DISC) study, which was a

multicenter, double-blind, randomized, placebo-controlled clinical trial in which adults with CF

were hospitalized for APE therapy and concurrently treated with a single high-dose vitamin D

bolus followed by maintenance supplementation of vitamin D_3 [36, 37]. We hypothesized that

vitamin D supplementation at the time of an APE for CF would improve glycemic control or

mitigate hyperglycemia and insulin resistance that is associated with critical illness.

2. Materials and Methods

2.1. Study design

This was a pre-planned secondary analysis of Vitamin D for the Immune System in

Cystic Fibrosis (DISC) trial [36], which is registered at clinicaltrials.gov as NCT01426256.

Briefly, the parent DISC trial was a multicenter, double-blind, placebo-controlled, intent-to-treat

clinical trial, spanning five Cystic Fibrosis Foundation Therapeutics Development Network

Centers: Emory University and Emory University Hospital (Atlanta, GA), Case Western Reserve

University and Rainbow Babies and Children's Hospital (Cleveland, OH), The University of

Alabama Hospital at Birmingham (Birmingham, AL), the University of Cincinnati and

University of Cincinnati Medical Center (Cincinnati, OH), and the University of Iowa and

University of Iowa Hospitals and Clinic (Iowa City, IA). Before trial participation, all study sites

received human studies approval from their local Institutional Review Boards. Within 72 hours

of hospital admission for an APE of CF, participants were randomized to receive a single dose of

vitamin D_3 (250,000 IU) orally or placebo. At the 3-month study visit, participants randomized to

oral vitamin D_3 took 50,000 IU of vitamin D_3 orally every 2 weeks, and participants randomized

to placebo took matching placebo orally every 2 weeks. Participants continued their regular

vitamin D supplementation if the amount was not greater than 2000 IU daily as recommended by

their respective healthcare providers.

2.2. Trial eligibility

As previously reported, participants were eligible for the DISC trial if they were 16 years

or older, admitted to the hospital for treatment of an APE of CF and enrolled into the study

within 72 hours of admission, able to tolerate oral medication, and expected to survive hospital

admission [37]. Participants were ineligible if they were unable to provide informed consent,

their serum total 25(OH)D concentration was <10 ng/mL or >55 ng/mL within the previous 12

months, had vitamin D intake >2000 IU daily or >10,000 IU vitamin D bolus within the past 60

days, had plans for pregnancy in the next 12 months, had conditions that could be exacerbated by

vitamin D such as current hypercalcemia, had conditions that affected vitamin D metabolism

such as chronic kidney disease or nephrolithiasis with active symptoms, had conditions that

affect survival (such as a history of organ transplantation, HIV/AIDS, illicit drug use, etc.), took

oral or intravenous glucocorticoids in the past month, forced expiratory volume in 1-second

present predicted (FEV1%) <20%, current hepatic dysfunction with total bilirubin >2.5 mg/dL

with direct bilirubin >1.0mg/dL, current use of cytotoxic or immunosuppressive drugs, or were

enrolled in any other interventional trial. The primary endpoints of the DISC trial were serial

lung function, time to next pulmonary exacerbation, 12-month mortality, and serial plasma

cathelicidin concentrations.

In this secondary analysis, participants were excluded if there was no available data on

HbA1c or fasting blood glucose level at baseline or the 12-month visit. This was a pre-planned

secondary analysis of the DISC parent trial. However, at the initiation of the parent study (2011),

studies investigating this topic had not yet been conducted.

2.3. Blood Analysis

Routine blood work was collected at the baseline visit during an APE and at the 12-

month visit after APE recovery. Values for HbA1c and fasting blood glucose levels were

measured by standard hospital methods, and the values were extracted from the electronic

medical record.

2.4. Statistical analysis

Demographics, HbA1c, and fasting blood glucose levels of participants were reported by

mean and their respective standard deviation. P-values for continuous variables were calculated

using a two-sample t-test assuming normal distribution and equal variances with significance set

at 0.05. A p-value was calculated to detect differences in change in HbA1c and fasting blood

glucose between the two groups. Categorical variables were listed as counts and their respective

percentages.

3. Results

3.1. Study participants

Ninety-one participants were enrolled in the parent DISC trial, and 49 participants were

eligible for this secondary analysis on glycemic control (Figure 1). The baseline demographic

characteristics between the vitamin D_3 and placebo groups were similar for this sub-group (Table

1). Participants randomized to vitamin D_3 or placebo had similar baseline serum 25(OH)D,

HbA1c, and fasting blood glucose levels (Table 1).

Figure 1. CONSORT diagram of completed DISC study with secondary endpoints.

Table 1. Baseline demographics of participants.

	Total (n = 49)	Vitamin D$_3$ (n = 22)	Placebo (n = 27)	P-value
Age (years)	29.2 ± 8.1	29.1 ± 8.0	29.3 ± 8.3	0.5

BMI (kg/m^2)	21.4 ± 4.0	21.8 ± 4.6	21.0 ± 3.5	0.2
Gender (%)				
- Male	29 (58%)	11 (47.8%)	18 (66.7%)	
- Female	21 (42%)	12 (52.2%)	9 (33.3%)	
Race (%)				
- Caucasian	45 (90%)	20 (87.0%)	25 (92.6%)	
- African American	5 (10%)	3 (13.0%)	2 (7.4%)	
CFTR mutation				
- Homozygous for f508del	45 (90%)	20 (87.0%)	25 (92.6%)	
- No copies of f508del	2 (4%)	2 (8.7%)	0 (0%)	
- Unknown	3 (6%)	1 (4.3%)	2 (7.4%)	
Baseline 25(OH)D (ng/mL)	26.8 ± 9.8	28.8 ± 10.8	25.2 ± 8.8	0.1
Baseline HbA1c (%)	6.3 ± 1.4	6.7 ± 1.8	6.1 ± 1.0	0.1
Baseline fasting blood glucose level (mg/dL)	100 ± 29.7 (n = 11)	105.1 ± 33.7 (n = 8)	87.3 ± 8.5 (n = 3)	0.4

3.2. Change in HbA1c after administration of a bolus dose of vitamin D_3 or placebo.

The mean change in HbA1c for all enrolled study participants was -0.055% ± 0.66. The mean

change in HbA1c over 12 months for study participants was not statistically significantly

different by treatment group (Table 2). Participants treated with the vitamin D_3 bolus (n = 22)

had a mean HbA1c change of -0.0318% ± 0.949 vs participants treated with placebo (n = 27) had

a change of -0.0740% ± 0.290 (p = 0.827) (Figure 2).

Table 2. Baseline to month 12 change in HbA1c and fasting blood glucose levels in participants

randomized to vitamin D$_3$ or placebo.

	Vitamin D$_3$ (n = 22)	Placebo (n = 27)	P-value
Δ HbA1c (%)	-0.03 ± 0.9	-0.07 ± 0.3	0.8
Δ Fasting blood glucose level (mg/dL)	0.8 ± 39.2 (n = 8)	15.7 ± 3.8 (n = 3)	0.5

Figure 2. Twelve-month change in HbA1c in study participants with an APE of CF randomized

to vitamin D$_3$ or placebo.

3.3. Change in fasting blood glucose after administration of a bolus dose of vitamin D$_3$ or

placebo.

The mean change in fasting blood glucose for all eligible participants was 4.82 mg/dL ±

33.57 (Table 2). The mean change in fasting blood glucose over 12 months for participants was

not significantly different by treatment group. Participants randomized to vitamin D_3 bolus (n =

8) had a mean fasting blood glucose change of 0.75 mg/dL ± 39.19 vs participants treated with

placebo (n = 3) had a change of 15.67 mg/dL ± 3.79 (p = 0.54) (Figure 3).

Figure 3. Twelve-month change in fasting blood glucose in study participants with an APE of

CF randomized to vitamin D_3 or placebo.

3.4. Baseline to 12-month change in glucose tolerance rating and CFRD status.

Glucose tolerance was also measured in 9 of the 50 participants, using the following

indicators: 1 - Normal glucose tolerance, 2 - Impaired fasting glucose, 3 - Impaired glucose

tolerance, 4 - CFRD with fasting hyperglycemia, 5 - CFRD without fasting hyperglycemia, 6 -

Unknown or indeterminate glucose tolerance (Table 3). Of the participants with glucose

tolerance recorded (n = 9), 5 participants had normal glycemic control (rating = 1) at baseline

and the 12-month follow-up regardless of treatment group. Of those with glucose tolerance

measured in the vitamin D group (n = 4), two participants' glucose tolerance remained the same,

one had worsened glycemic control, and one had improved glycemic control. Of participants in

the placebo group (n = 5), 4 participants' glucose tolerance remained the same, and one had

improved tolerance. Of the nine participants with glycemic control measured, 2 participants (one

in the vitamin D group and one in the placebo group) had CFRD at baseline, and both had

improved glycemic control at the endpoint. The participant in the vitamin D group improved

from CFRD without fasting hyperglycemia (rating = 5) to only impaired glucose tolerance

(rating = 3). The participant in the placebo group improved from CFRD with fasting

hyperglycemia (rating = 4) to normal glucose tolerance (rating = 1). Within this nine-patient

subgroup, all participants, except one, had stable glucose tolerance (same rating at both time

points) (n = 6) or improved glucose tolerance (n = 2) from baseline to the 12-month endpoint

regardless of the treatment group.

Table 3. Baseline and month 12 glucose tolerance rating with the following scale: [1 - Normal

glucose tolerance, 2 - Impaired fasting glucose, 3 - Impaired glucose tolerance, 4 - CFRD with

fasting hyperglycemia, 5 - CFRD without fasting hyperglycemia, 6 - Unknown or indeterminate

glucose tolerance].

Vitamin D group (n = 4)	Baseline rating	Month 12 rating
Patient 1	5	3
Patient 2	1	3
Patient 3	3	3
Patient 4	1	1

Placebo group (n = 5)	Baseline rating	Month 12 rating
Patient 1	1	1
Patient 2	4	1
Patient 3	1	1
Patient 4	1	1
Patient 5	1	1

4. Discussion

The purpose of this secondary analysis was to determine the role of a single high-bolus

dose and maintenance vitamin D dosing of vitamin D_3 on glycemic control in participants with

CF after an APE. Based on the understanding that a critical illness can commonly cause an

increase in insulin resistance and hyperglycemia, we intended for this secondary analysis to

examine if there were any therapeutic effects of vitamin D supplementation to counteract the

likely decline in glycemic control following an APE. We found that administration of a single

vitamin D_3 bolus in participants with CF at the time of hospital admission for an APE followed

by bi-weekly bolus doses of vitamin D for one year did not result in significant changes in

HbA1c and fasting blood glucose levels compared to placebo. Despite this, all participants with

glucose tolerance measured, except one, had stable glucose tolerance (same rating at baseline

and month 12) (n = 6) or improved glucose tolerance (n = 2) regardless of the treatment group

they were assigned. Additionally, participants randomized to vitamin D_3 showed fasting blood

glucose levels increased less than those randomized to placebo, although, these results were

underpowered. The increase in fasting blood glucose levels for both groups could be considered

predictable given the history of an APE, and therefore, vitamin D supplementation may have

mitigated the negative effects on glycemic control that were caused by the APE. Our findings

suggest that the administration of a vitamin D_3 bolus dose may not be beneficial for long-term

glycemic control in participants with CF or that the duration and/or dosage of vitamin D

administration were not adequate to detect a significant difference.

Our secondary analysis determined that vitamin D supplementation after an APE did not

induce a significant improvement in glycemic control in patients with CF. Therefore, it may not

be beneficial for patients with CF, who are not vitamin D deficient, to take supplemental vitamin

D. However, it should be considered that during an APE, patients with CF very commonly

develop hyperglycemia, which seems to not improve in the long-term [34]; we may have not

detected significant changes due to this consideration. Because vitamin D may not have a

significant therapeutic effect on glycemic control, it is important to consider alternatives that

may be more beneficial, given that hyperglycemia and lung function decline seem to be

associated. A meta-analysis of randomized controlled trials (RCTs) on type 2 diabetes treatments,

specifically sodium glucose cotransport-2 (SGLT-2) inhibitors and glucagon-like peptide-1

(GLP-1) receptor agonists, indicated improved health-related quality of life, reduced all-cause

mortality, improved end-stage kidney disease, and lowered risk of hospitalization for heart

failure; these two drug classes are specifically beneficial to adults with elevated risk for

cardiovascular and kidney complications [38]. However, SGLT-2 inhibitors are associated with

genitourinary infections, ketoacidosis, acute renal injury, etc. [39], and GLP-1 receptor agonists

are associated with pre-renal acute kidney injury and various mild gastrointestinal symptoms

[40]. An umbrella review of Mendelian randomization (MR) studies and RCTs indicated low

vitamin D was a causal risk factor for type 2 diabetes [41]. The meta-analysis concluded vitamin

D supplementation may have some therapeutic and long-term preventative effects on chronic

diseases (such as type 2 diabetes, hypertension, Alzheimer's disease, and schizophrenia) and

decrease all-cause mortality; however, the current implementation, which utilizes vitamin D as

an intervention for the diseases, might not be efficient, thus, more effective strategies are needed

to improve the outcomes of vitamin D supplementation as an intervention for chronic diseases

[41]. Adults with higher 25(OH)D levels (genetically predicated and lifelong) are at higher risk

for kidney stone disease, partially via elevated calcium levels [42]. In comparing the risks and

benefits of vitamin D supplementation vs. drugs designed for type 2 diabetes, vitamin D is less

likely to induce severe side effects (unless there is prior genetic predisposition). Therefore, it

would be extremely beneficial to elucidate a highly efficient and effective method utilizing

vitamin D as an interventional therapeutic.

In the context of CF, hyperglycemia is highly prevalent during pulmonary exacerbations

[34]. Animal models show that increased glucose concentration within the airways promotes the

growth of bacteria and negatively alters immune function, reducing phagocytosis of neutrophils

and chemokinesis [13, 43, 44], possibly leading to more frequent APEs and worsened recovery.

Upon hospital admission for an APE, a study showed 8/9 pediatric patients with CF had

hyperglycemia (2 CFRD, 6 abnormal oral glucose tolerance test (OGTT)), and 2 weeks later, 5/8

had hyperglycemia (2 CFRD, 3 abnormal OGTT); at follow-up (3.8-6.3 months), glucose

tolerance declined after the initial improvement [34]. It is possible that hyperglycemia initially

improved after antibiotic treatment for the pulmonary exacerbation due to reduced inflammation,

as inflammation is associated with increased insulin resistance and decreased secretion of

insulin; however, long-term effects of exacerbation-associated inflammation or untreated

hyperglycemia may have contributed to damaging or toxic effects on beta cells, reducing beta

cell function and insulin secretion [34]. Without treatment for hyperglycemia after an APE, there

seems to be glycemic control improvement in the short term but a decline in the long term.

Further, morbidity and acquired infections during hospitalization significantly decrease after

treating hyperglycemia [44]. Therefore, based on previous studies showing some therapeutic

promise of vitamin D supplementation, we proposed vitamin D may be able to treat

hyperglycemia to improve the quality of life of patients with CF after an APE.

Several studies show that vitamin D is needed for optimal glucose metabolism and

homeostasis [26, 45, 46]. Vitamin D intake is believed to decrease the prevalence of type 2

diabetes through stimulation of gene expression of insulin receptors and improving transport of

glucose from the intestine [47, 48]. A study in human promonocytic cells showed that insulin

receptor capacity and insulin-stimulated glucose transport increased when activated by

$25(OH)_2D_3$ [25, 48, 49]. Vitamin D supplementation was seen to improve glycemic control in

only participants with vitamin D deficiency and had no therapeutic effects for participants

already within the normal range of 25(OH)D [50]. These previous studies suggest that vitamin D

may be important for glucose metabolism in people who have vitamin D deficiency and who are

at risk for diabetes. This may be the reason for the lack of therapeutic effects in this secondary

analysis.

However, some prior research supports our findings that vitamin D supplementation does

not improve glycemic control. A study showed that vitamin D_3 supplementation normalizes

25(OH)D concentration in patients with diabetes but may not have long-term effects on glycemic

control [51]. The large-scale Vitamin D and Type 2 Diabetes (D2d) study (n = 2423) concluded

that two-year vitamin D supplementation, 4,000 IU daily, in patients with vitamin D deficiency

did not result in significantly lower risk of diabetes as compared to placebo, despite differences

in $25(OH)D_3$ at month 24 (54.3 ng/mL in vitamin D group vs 28.8 ng/mL in placebo group) [25].

Further, a systematic review of 13 randomized controlled trials on the role of vitamin D

supplementation in the prevention of type 2 diabetes indicated that vitamin D supplementation

had no statistically significant impact on the incidence of type 2 diabetes in six of the seven trials

that identified type 2 diabetes incidence as a research outcome [52-65]. Additionally, 10 of the

trials analyzed the impact of vitamin D supplementation on insulin resistance using the

Homeostatic Model Assessment for Insulin resistance (HOMA-IR). In six of the trials, patients

who received vitamin D supplementation had lowered and improved insulin resistance while the

four remaining trials had conflicting results [52]. However, these trials ranged from 12 weeks to

60 months, in which vitamin D dosage, vitamin D-deficient status, diabetes status, and body

mass index (BMI) varied widely, possibly contributing to conflicting results on the efficacy of

vitamin D [52]. In a separate review, where over 15 RCTs were reviewed, vitamin D

supplementation did not improve HbA1c, insulin resistance, or fasting blood glucose [35].

However, in four of the trials, prediabetic subjects who received vitamin D supplementation had

improved fasting plasma glucose [52]. Similarly, Farahmand et. al. found that vitamin D

supplementation was associated with reduced HbA1c when participants were vitamin D deficient

at baseline [66]. Thus, prior findings have indicated conflicting results regarding the therapeutic

effects of vitamin D on glycemic control, especially regarding optimal dosage and duration. It

remains unresolved whether specific populations, such as those with prediabetes, may benefit

from vitamin D supplementation.

Study limitations include the number of participants eligible within the secondary study,

the timing of vitamin D_3 intervention, the severity of the APE, baseline vitamin D status, and

only one end timepoint (12-month) used for comparison to baseline. Future studies may find it

useful to examine glycemic biomarkers at additional time points. As a secondary analysis, the

sample size may not have been large enough to conclude statistically significant changes in

glycemic control. However, this data provides some initial impressions of the effect of this

intervention on glycemic control after an APE and may inform the study design of future studies.

The participants involved in the study were admitted following an APE, in which the timing of

the bolus dose of vitamin D_3 may not be appropriate for improvement in glycemic control. After

critical illness, such as an APE, it is common for hyperglycemia and insulin resistance to develop

[33], possibly explaining the rise in HbA1c despite vitamin D supplementation. In a study

conducted in 9 pediatric patients following CF exacerbation, hyperglycemia was highly

prevalent, which seemed to improve after treatment for the exacerbation and worsen later on

when insulin secretion decreased as well [34]. CFRD development has been associated with

worsened lung function and disease, and insulin therapy has been seen to improve these

symptoms [11]. A retrospective study in children showed recovery from exacerbations can be

altered by untreated hyperglycemia [12]. Following hospital admission, many participants were

recovering from the effects of APE and still receiving antibiotics. Prolonged use of antibiotics

has been associated with a higher risk of developing diabetes [67]. Additionally, at baseline,

participants in both groups had a mean $25(OH)D_3$ level considered adequate (>20 ng/mL). In our

analysis, at baseline in the vitamin D group, participants' 25(OH)D was 28.8 ng/mL ± 10.8, and

participants in the placebo group's 25(OH)D was 25.2 ng/mL ± 8.8. Therefore, on average,

participants in both groups were not vitamin D deficient at baseline. Previous studies show that

vitamin D_3 supplementation was beneficial in instances where patients were vitamin D deficient

(25(OH)D <20 ng/mL) [50]. In future studies, it may be beneficial to measure HbA1c and fasting

blood glucose at more time points to evaluate both the short-term and long-term effects of an

APE on hyperglycemia as well as the effect of vitamin D on glycemic control at different time

points during recovery from the APE. This secondary analysis provides initial impressions of the

effect of vitamin D supplementation on an APE of CF and may inform future study designs

based on these limitations.

In conclusion, high-dose bolus vitamin D_3 treatment upon hospital admission for an APE,

followed by maintenance vitamin D dosing, did not improve glycemic control after 1 year in

adults with CF. Although there are many conflicting studies regarding the effect of vitamin D

supplementation on hyperglycemia, the results from our secondary analysis of the DISC study

support some prior findings that vitamin D supplementation may not improve glycemic control

despite its possible effect on insulin resistance. However, the added nuance of previously

documented hyperglycemia and insulin resistance during and after an APE should be considered,

as vitamin D may have had some therapeutic effect that was not detected or significant. More

adults with CF are developing CFRD due to increasing rates of survival and increased incidence

of overweight and obesity. The findings from this secondary analysis suggest that high-dose

bolus vitamin D_3 administration (during hospital admission of an APE of CF) and patient

population (not deficient in vitamin D_3 and/or prior glucose tolerance status) did not impact

glycemic control. Future studies may elucidate whether poor glycemic control results in declined

FEV1 recovery or if biomarkers for poor glycemic control are indications of worsened disease.

Further research with rigorous evaluation of blood glucose control with continuous glucose

monitoring and more frequent measurements of HbA1C over time is required to investigate the

impact of vitamin D_3 on patients with CF after an APE, especially those with vitamin D

deficiency and at high risk for diabetes.

Author Contributions: The authors' contributions were as follows – VT and JAA: designed the

study and obtained funding; VT, JAA, TRZ, and WRH: performed and supervised the conduct of

the trial and revised the manuscript; AS and VT: performed secondary analysis, verified,

interpreted the data, and revised the manuscript; AS performed statistically analyses and drafted

the manuscript.

Funding: This study was supported by CFF Awards TANGPR19A0 and TANGPR11A0 (to VT),

CC002-AD, and NIH grants UL1 TR000454 (Emory CTSA), UL1 TR00165 (UAB CTSA), T32

DK007298 (to JAA), T32 DK007734 (to ESM), K24 DK096574 (to TRZ), and K01 DK102851

(to JAA), P30DK125013, and 3UL1TR002378-05S2. The CF Foundation and NIH had no roles

in study design, data collection, analysis, interpretation, or writing of the report. The

corresponding author had full access to all the data in the study and had final responsibility for

the decision to submit for publication.

Acknowledgments: The study investigators would like to acknowledge the participants and

study team in the Vitamin D for Enhancing the Immune System in Cystic Fibrosis clinical trial.

Conflicts of Interest: All the authors have read and approved the final manuscript. None of the

authors reported a conflict of interest related to the study.

References

1. Kayani K, Mohammed R, Mohiaddin H. Cystic Fibrosis-Related Diabetes. Front

Endocrinol (Lausanne). 2018 Feb 20;9:20. doi: 10.3389/fendo.2018.00020. PMID:

29515516; PMCID: PMC5826202.

2. Morrison CB, Markovetz MR, Ehre C. Mucus, mucins, and cystic fibrosis. Pediatr

Pulmonol. 2019 Nov;54 Suppl 3(Suppl 3):S84-S96. doi: 10.1002/ppul.24530. PMID:

31715083; PMCID: PMC6853602.

3. Ehre C, Ridley C, Thornton DJ. Cystic fibrosis: an inherited disease affecting mucin-

producing organs. Int J Biochem Cell Biol. 2014 Jul;52:136-45. doi:

10.1016/j.biocel.2014.03.011. Epub 2014 Mar 28. PMID: 24685676; PMCID:

PMC4449140.

4. Chesdachai S, Tangpricha V. Treatment of vitamin D deficiency in cystic fibrosis. J

Steroid Biochem Mol Biol. 2016 Nov;164:36-39. doi: 10.1016/j.jsbmb.2015.09.013.

Epub 2015 Sep 10. PMID: 26365559; PMCID: PMC4786457.

5. Hall WB, Sparks AA, Aris RM. Vitamin D deficiency in cystic fibrosis. Int J Endocrinol.

2010;2010:218691. doi: 10.1155/2010/218691. Epub 2010 Jan 28. PMID: 20148079;

PMCID: PMC2817861.

6. Mariotti Zani E, Grandinetti R, Cunico D, Torelli L, Fainardi V, Pisi G, Esposito S.

Nutritional Care in Children with Cystic Fibrosis. Nutrients. 2023 Jan 17;15(3):479. doi:

10.3390/nu15030479. PMID: 36771186; PMCID: PMC9921127.

7. Daley T, Hughan K, Rayas M, Kelly A, Tangpricha V. Vitamin D deficiency and its

treatment in cystic fibrosis. J Cyst Fibros. 2019 Oct;18 Suppl 2:S66-S73. doi:

10.1016/j.jcf.2019.08.022. PMID: 31679731.

8. Wood C, Hasan S, Darukhanavala A, Tangpricha V. A Clinician's guide to vitamin D

supplementation for patients with cystic fibrosis. J Clin Transl Endocrinol. 2021 Nov

6;26:100273. doi: 10.1016/j.jcte.2021.100273. PMID: 34815946; PMCID: PMC8593649.

9. Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC, Klein DJ.

Diabetes mellitus associated with cystic fibrosis. J Pediatr. 1988 Mar;112(3):373-7. doi:

10.1016/s0022-3476(88)80315-9. PMID: 3346774.

10. Prentice B, Nicholson M, Lam GY. Cystic fibrosis related diabetes (CFRD) in the era of

modulators: A scoping review. Paediatr Respir Rev. 2023 Jun;46:23-29. doi:

10.1016/j.prrv.2022.11.005. Epub 2022 Dec 5. PMID: 36581478.

11. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of

insulin therapy on lung function and infections. Acta Paediatr. 1994 Aug;83(8):849-53.

doi: 10.1111/j.1651-2227.1994.tb13156.x. PMID: 7981562.

12. Okoniewski W, Hughan KS, Weiner GA, Weiner DJ, Forno E. Glycemic control and

FEV_1 recovery during pulmonary exacerbations in pediatric cystic fibrosis-related

diabetes. J Cyst Fibros. 2020 May;19(3):460-465. doi: 10.1016/j.jcf.2019.12.016. Epub

2020 Jan 22. PMID: 31980357; PMCID: PMC7329580.

13. Brennan AL, Gyi KM, Wood DM, Johnson J, Holliman R, Baines DL, Philips BJ, Geddes

DM, Hodson ME, Baker EH. Airway glucose concentrations and effect on growth of

respiratory pathogens in cystic fibrosis. J Cyst Fibros. 2007 Apr;6(2):101-9. doi:

10.1016/j.jcf.2006.03.009. Epub 2006 Jul 17. PMID: 16844431.

14. Inman TB, Proudfoot JA, Lim M, Demeterco-Berggren C. Continuous glucose

monitoring in a cystic fibrosis patient to predict pulmonary exacerbation? J Cyst Fibros.

2017 Sep;16(5):628-630. doi: 10.1016/j.jcf.2017.05.009. Epub 2017 Jul 29. PMID:

28625799.

15. Lee J, Lee YJ, Kim Y. A high prevalence of prediabetes and vitamin D deficiency are

more closely associated in women: results of a cross-sectional study. J Int Med Res. 2021

Jul;49(7):3000605211033384. doi: 10.1177/03000605211033384. PMID: 34334004;

PMCID: PMC8326633.

16. Szymczak-Pajor I, Śliwińska A. Analysis of Association between Vitamin D Deficiency

and Insulin Resistance. Nutrients. 2019 Apr 6;11(4):794. doi: 10.3390/nu11040794.

PMID: 30959886; PMCID: PMC6520736.

17. Leung PS. The Potential Protective Action of Vitamin D in Hepatic Insulin Resistance

and Pancreatic Islet Dysfunction in Type 2 Diabetes Mellitus. Nutrients. 2016 Mar

5;8(3):147. doi: 10.3390/nu8030147. PMID: 26959059; PMCID: PMC4808876.

18. Yu L, Zhai Y, Shen S. Association between vitamin D and prediabetes: A PRISMA-

compliant meta-analysis. Medicine (Baltimore). 2020 Feb;99(8):e19034. doi:

10.1097/MD.0000000000019034. PMID: 32080077; PMCID: PMC7034644.

19. Khudayar M, Nadeem A, Lodi MN, Rehman K, Jawaid SI, Mehboob A, Aleem AS,

Mirza REF, Ahmed M, Abbas K. The Association Between Deficiency of Vitamin D and

Diabetes Mellitus Type 2 (DMT2). Cureus. 2022 Feb 14;14(2):e22221. doi:

10.7759/cureus.22221. PMID: 35340511; PMCID: PMC8930435.

20. Vijay GS, Ghonge S, Vajjala SM, Palal D. Prevalence of Vitamin D Deficiency in Type 2

Diabetes Mellitus Patients: A Cross-Sectional Study. Cureus. 2023 May 12;15(5):e38952.

doi: 10.7759/cureus.38952. PMID: 37313077; PMCID: PMC10258395.

21. Contreras-Bolívar V, García-Fontana B, García-Fontana C, Muñoz-Torres M.

Mechanisms Involved in the Relationship between Vitamin D and Insulin Resistance:

Impact on Clinical Practice. Nutrients. 2021 Oct 1;13(10):3491. doi:

10.3390/nu13103491. PMID: 34684492; PMCID: PMC8539968.

22. Berridge MJ. Vitamin D deficiency and diabetes. Biochem J. 2017 Mar 24;474(8):1321-

1332. doi: 10.1042/BCJ20170042. PMID: 28341729.

23. Khazai N, Judd SE, Tangpricha V. Calcium and vitamin D: skeletal and extraskeletal

health. Curr Rheumatol Rep. 2008 Apr;10(2):110-7. doi: 10.1007/s11926-008-0020-y.

PMID: 18460265; PMCID: PMC2669834.

24. Mirhosseini N, Vatanparast H, Mazidi M, Kimball SM. Vitamin D Supplementation,

Glycemic Control, and Insulin Resistance in Prediabetics: A Meta-Analysis. J Endocr

Soc. 2018 May 25;2(7):687-709. doi: 10.1210/js.2017-00472. PMID: 29951596; PMCID:

PMC6016617.

25. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2

diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007

Jun;92(6):2017-29. doi: 10.1210/jc.2007-0298. Epub 2007 Mar 27. PMID: 17389701;

PMCID: PMC2085234.

26. Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium

supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults

at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM)

randomized controlled trial. Am J Clin Nutr. 2011 Aug;94(2):486-94. doi: 10.3945/ajcn.111.011684. Epub 2011 Jun 29. PMID: 21715514; PMCID: PMC3142723.

27. Gagnon C, Daly RM, Carpentier A, Lu ZX, Shore-Lorenti C, Sikaris K, Jean S, Ebeling PR. Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and β-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial. PLoS One. 2014 Oct 9;9(10):e109607. doi: 10.1371/journal.pone.0109607. PMID: 25299668; PMCID: PMC4192133.

28. Peng Y, Wu M, Alvarez JA, Tangpricha V. Vitamin D Status and Risk of Cystic Fibrosis-Related Diabetes: A Retrospective Single Center Cohort Study. Nutrients. 2021 Nov 12;13(11):4048. doi: 10.3390/nu13114048. PMID: 34836301; PMCID: PMC8619506.

29. Singh A, Singh N. Vitamin D intervention as a curative measure for glucose intolerance in obese children and adolescents: a systematic review on randomized control trials. Eur J Pediatr. 2024 Jan 11. doi: 10.1007/s00431-023-05407-0. Epub ahead of print. PMID: 38206398.

30. Vera Castro MF, Assmann CE, Reichert KP, Coppetti PM, Stefanello N, da Silva AD, Mostardeiro VB, de Jesus LB, da Silveira MV, Schirmann AA, Fracasso M, Maciel RM, Morsch VMM, Schetinger MRC. Vitamin D3 mitigates type 2 diabetes induced by a high carbohydrate-high fat diet in rats: role of the purinergic system. J Nutr Biochem. 2024 Feb 17:109602. doi: 10.1016/j.jnutbio.2024.109602. Epub ahead of print. PMID: 38373509.

31. Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, Jones PW. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with

acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006

Apr;61(4):284-9. doi: 10.1136/thx.2005.051029. Epub 2006 Jan 31. PMID: 16449265;

PMCID: PMC2104606.

32. Robinson LE, van Soeren MH. Insulin resistance and hyperglycemia in critical illness:

role of insulin in glycemic control. AACN Clin Issues. 2004 Jan-Mar;15(1):45-62. doi:

10.1097/00044067-200401000-00004. PMID: 14767364.

33. Li L, Messina JL. Acute insulin resistance following injury. Trends Endocrinol Metab.

2009 Nov;20(9):429-35. doi: 10.1016/j.tem.2009.06.004. Epub 2009 Oct 1. PMID:

19800814; PMCID: PMC2939005.

34. Merjaneh L, Toprak D, McNamara S, Nay L, Sullivan E, Rosenfeld M. Acute

hyperglycaemia in cystic fibrosis pulmonary exacerbations. Endocrinol Diabetes Metab.

2020 Nov 30;4(2):e00208. doi: 10.1002/edm2.208. PMID: 33855211; PMCID:

PMC8029509.

35. Elidottir H, Diemer S, Eklund E, Hansen CR. Abnormal glucose tolerance and lung

function in children with cystic fibrosis. Comparing oral glucose tolerance test and

continuous glucose monitoring. J Cyst Fibros. 2021 Sep;20(5):779-784. doi:

10.1016/j.jcf.2021.01.002. Epub 2021 Jan 19. PMID: 33478894.

36. Tangpricha V, Lukemire J, Chen Y, Binongo JNG, Judd SE, Michalski ES, Lee MJ,

Walker S, Ziegler TR, Tirouvanziam R, Zughaier SM, Chesdachai S, Hermes WA,

Chmiel JF, Grossmann RE, Gaggar A, Joseph PM, Alvarez JA. Vitamin D for the

Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized,

placebo-controlled clinical trial. Am J Clin Nutr. 2019 Mar 1;109(3):544-553. doi:

10.1093/ajcn/nqy291. Erratum in: Am J Clin Nutr. 2023 May;117(5):1048. PMID:

30793177; PMCID: PMC6408205.

37. Tangpricha V, Smith EM, Binongo J, Judd SE, Ziegler TR, Walker S, Tirouvanziam R,

Zughaier SM, Lee MJ, Chesdachai S, Hermes WA, Chmiel JF, Gaggar A, Grossmann RE,

Joseph PM, Alvarez JA. The Vitamin D for Enhancing the Immune System in Cystic

Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-

controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary

exacerbation of cystic fibrosis. Contemp Clin Trials Commun. 2017 Jun;6:39-45. doi:

10.1016/j.conctc.2017.02.010. Epub 2017 Mar 9. PMID: 28508087; PMCID:

PMC5427007.

38. Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, Marx N, Brosius FC 3rd,

Mustafa RA, Agarwal A, Zou X, Mao Y, Asadollahifar A, Chowdhury SR, Zhai C, Gupta

S, Gao Y, Lima JP, Numata K, Qiao Z, Fan Q, Yang Q, Jin Y, Ge L, Yang Q, Zhu H, Yang

F, Chen Z, Lu X, He S, Chen X, Lyu X, An X, Chen Y, Hao Q, Standl E, Siemieniuk R,

Agoritsas T, Tian H, Li S. Benefits and harms of drug treatment for type 2 diabetes:

systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023

Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068. PMID: 37024129; PMCID:

PMC10077111.

39. Pittampalli S, Upadyayula S, Mekala HM, Lippmann S. Risks vs Benefits for SGLT2

Inhibitor Medications. Fed Pract. 2018 Jul;35(7):45-48. PMID: 30766374; PMCID:

PMC6368009.

40. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor

Agonists. Rev Diabet Stud. 2014 Fall-Winter;11(3-4):202-30. doi:

10.1900/RDS.2014.11.202. Epub 2015 Feb 10. PMID: 26177483; PMCID:

PMC5397288.

41. Liu D, Meng X, Tian Q, Cao W, Fan X, Wu L, Song M, Meng Q, Wang W, Wang Y.

Vitamin D and Multiple Health Outcomes: An Umbrella Review of Observational

Studies, Randomized Controlled Trials, and Mendelian Randomization Studies. Adv

Nutr. 2022 Aug 1;13(4):1044-1062. doi: 10.1093/advances/nmab142. PMID: 34999745;

PMCID: PMC9340982.

42. Jian Z, Huang Y, He Y, Jin X, Li H, Li S, Wang K. Genetically Predicted Lifelong

Circulating 25(OH)D Levels are Associated With Serum Calcium Levels and Kidney

Stone Risk. J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1159-e1166. doi:

10.1210/clinem/dgab758. PMID: 34669929.

43. Hunt WR, Zughaier SM, Guentert DE, Shenep MA, Koval M, McCarty NA, Hansen JM.

Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-

related diabetes. Am J Physiol Lung Cell Mol Physiol. 2014 Jan 1;306(1):L43-9. doi:

10.1152/ajplung.00224.2013. Epub 2013 Oct 4. PMID: 24097557; PMCID:

PMC3920212.

44. Srinivasan V, Agus MS. Tight glucose control in critically ill children--a systematic

review and meta-analysis. Pediatr Diabetes. 2014 Mar;15(2):75-83. doi:

10.1111/pedi.12134. PMID: 24783254.

45. Lim S, Kim MJ, Choi SH, Shin CS, Park KS, Jang HC, Billings LK, Meigs JB.

Association of vitamin D deficiency with incidence of type 2 diabetes in high-risk Asian

subjects. Am J Clin Nutr. 2013 Mar;97(3):524-30. doi: 10.3945/ajcn.112.048496. Epub

2013 Jan 30. PMID: 23364011; PMCID: PMC3578401.

46. Yousefi Rad E, Djalali M, Koohdani F, Saboor-Yaraghi AA, Eshraghian MR, Javanbakht

MH, Saboori S, Zarei M, Hosseinzadeh-Attar MJ. The Effects of Vitamin D

Supplementation on Glucose Control and Insulin Resistance in Patients with Diabetes

Type 2: A Randomized Clinical Trial Study. Iran J Public Health. 2014 Dec;43(12):1651-

6. PMID: 26171357; PMCID: PMC4499086.

47. Ozfirat Z, Chowdhury TA. Vitamin D deficiency and type 2 diabetes. Postgrad Med J.

2010 Jan;86(1011):18-25; quiz 24. doi: 10.1136/pgmj.2009.078626. PMID: 20065337.

48. Maestro B, Campión J, Dávila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of

insulin receptor expression and insulin responsiveness for glucose transport in U-937

human promonocytic cells. Endocr J. 2000 Aug;47(4):383-91. doi:

10.1507/endocrj.47.383. PMID: 11075718.

49. Bland R, Markovic D, Hills CE, Hughes SV, Chan SL, Squires PE, Hewison M.

Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid

Biochem Mol Biol. 2004 May;89-90(1-5):121-5. doi: 10.1016/j.jsbmb.2004.03.115.

PMID: 15225758.

50. Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic

control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr.

2009 Sep;48(6):349-54. doi: 10.1007/s00394-009-0020-3. Epub 2009 Apr 16. PMID:

19370371.

51. Ryu OH, Lee S, Yu J, Choi MG, Yoo HJ, Mantero F. A prospective randomized controlled

trial of the effects of vitamin D supplementation on long-term glycemic control in type 2

diabetes mellitus of Korea. Endocr J. 2014;61(2):167-76. doi: 10.1507/endocrj.ej13-0356.

Epub 2013 Nov 16. PMID: 24240575.

52. Khan Z, Muhammad SA, Carpio J, Yousif Y, Gul A, Hamid S, Gupta A. The Effect of

Vitamin D Supplementation on Incidence of Type 2 Diabetes: A Systematic Review.

Cureus. 2023 Mar 27;15(3):e36775. doi: 10.7759/cureus.36775. PMID: 37123701;

PMCID: PMC10133782.

53. Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, Brodsky I,

Ceglia L, Chadha C, Chatterjee R, Desouza C, Dolor R, Foreyt J, Fuss P, Ghazi A, Hsia

DS, Johnson KC, Kashyap SR, Kim S, LeBlanc ES, Lewis MR, Liao E, Neff LM, Nelson

J, O'Neil P, Park J, Peters A, Phillips LS, Pratley R, Raskin P, Rasouli N, Robbins D,

Rosen C, Vickery EM, Staten M; D2d Research Group. Vitamin D Supplementation and

Prevention of Type 2 Diabetes. N Engl J Med. 2019 Aug 8;381(6):520-530. doi:

10.1056/NEJMoa1900906. Epub 2019 Jun 7. PMID: 31173679; PMCID: PMC6993875.

54. Dutta D, Mondal SA, Choudhuri S, Maisnam I, Hasanoor Reza AH, Bhattacharya B,

Chowdhury S, Mukhopadhyay S. Vitamin-D supplementation in prediabetes reduced

progression to type 2 diabetes and was associated with decreased insulin resistance and

systemic inflammation: an open label randomized prospective study from Eastern India.

Diabetes Res Clin Pract. 2014 Mar;103(3):e18-23. doi: 10.1016/j.diabres.2013.12.044.

Epub 2014 Jan 6. PMID: 24456991.

55. Jorde R, Sollid ST, Svartberg J, Schirmer H, Joakimsen RM, Njølstad I, Fuskevåg OM,

Figenschau Y, Hutchinson MY. Vitamin D 20,000 IU per Week for Five Years Does Not

Prevent Progression From Prediabetes to Diabetes. J Clin Endocrinol Metab. 2016

Apr;101(4):1647-55. doi: 10.1210/jc.2015-4013. Epub 2016 Feb 1. PMID: 26829443.

56. Salehpour A, Shidfar F, Hosseinpanah F, Vafa M, Razaghi M, Amiri F. Does vitamin D3

supplementation improve glucose homeostasis in overweight or obese women? A double-

blind, randomized, placebo-controlled clinical trial. Diabet Med. 2013 Dec;30(12):1477-

81. doi: 10.1111/dme.12273. Epub 2013 Jul 27. PMID: 23822797.

57. Al Thani M, Sadoun E, Sofroniou A, Jayyousi A, Baagar KAM, Al Hammaq A, Vinodson

B, Akram H, Bhatti ZS, Nasser HS, Leventakou V. The effect of vitamin D

supplementation on the glycemic control of pre-diabetic Qatari patients in a randomized

control trial. BMC Nutr. 2019 Oct 10;5:46. doi: 10.1186/s40795-019-0311-x. PMID:

32153959; PMCID: PMC7050821.

58. Moreira-Lucas TS, Duncan AM, Rabasa-Lhoret R, Vieth R, Gibbs AL, Badawi A,

Wolever TM. Effect of vitamin D supplementation on oral glucose tolerance in

individuals with low vitamin D status and increased risk for developing type 2 diabetes

(EVIDENCE): A double-blind, randomized, placebo-controlled clinical trial. Diabetes

Obes Metab. 2017 Jan;19(1):133-141. doi: 10.1111/dom.12794. Epub 2016 Nov 9.

PMID: 27717236.

59. Oosterwerff MM, Eekhoff EM, Van Schoor NM, Boeke AJ, Nanayakkara P, Meijnen R,

Knol DL, Kramer MH, Lips P. Effect of moderate-dose vitamin D supplementation on

insulin sensitivity in vitamin D-deficient non-Western immigrants in the Netherlands: a

randomized placebo-controlled trial. Am J Clin Nutr. 2014 Jul;100(1):152-60. doi:

10.3945/ajcn.113.069260. Epub 2014 Jun 4. PMID: 24898240.

60. Rasouli N, Brodsky IG, Chatterjee R, Kim SH, Pratley RE, Staten MA, Pittas AG; D2d

Research Group. Effects of Vitamin D Supplementation on Insulin Sensitivity and

Secretion in Prediabetes. J Clin Endocrinol Metab. 2022 Jan 1;107(1):230-240. doi:

10.1210/clinem/dgab649. PMID: 34473295; PMCID: PMC8684490.

61. Wallace HJ, Holmes L, Ennis CN, Cardwell CR, Woodside JV, Young IS, Bell PM,

Hunter SJ, McKinley MC. Effect of vitamin D3 supplementation on insulin resistance

and β-cell function in prediabetes: a double-blind, randomized, placebo-controlled trial.

Am J Clin Nutr. 2019 Nov 1;110(5):1138-1147. doi: 10.1093/ajcn/nqz171. PMID:

31559433.

62. Forouhi NG, Menon RK, Sharp SJ, Mannan N, Timms PM, Martineau AR, Rickard AP,

Boucher BJ, Chowdhury TA, Griffiths CJ, Greenwald SE, Griffin SJ, Hitman GA. Effects

of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk

among people at risk of type 2 diabetes: results of a randomized double-blind placebo-

controlled trial. Diabetes Obes Metab. 2016 Apr;18(4):392-400. doi: 10.1111/dom.12625.

Epub 2016 Feb 4. PMID: 26700109; PMCID: PMC4950066.

63. Ahmed MM, Zingade US, Badaam KM. Effect of Vitamin D3 Supplementation on

Insulin Sensitivity in Prediabetes With Hypovitaminosis D: A Randomized Placebo-

Controlled Trial. Cureus. 2020 Dec 10;12(12):e12009. doi: 10.7759/cureus.12009. PMID:

33457118; PMCID: PMC7797427.

64. Kawahara T, Suzuki G, Mizuno S, Inazu T, Kasagi F, Kawahara C, Okada Y, Tanaka Y.

Effect of active vitamin D treatment on development of type 2 diabetes: DPVD

randomised controlled trial in Japanese population. BMJ. 2022 May 25;377:e066222.

doi: 10.1136/bmj-2021-066222. PMID: 35613725; PMCID: PMC9131780.

65. Sollid ST, Hutchinson MY, Fuskevåg OM, Figenschau Y, Joakimsen RM, Schirmer H,

Njølstad I, Svartberg J, Kamycheva E, Jorde R. No effect of high-dose vitamin D

supplementation on glycemic status or cardiovascular risk factors in subjects with

prediabetes. Diabetes Care. 2014 Aug;37(8):2123-31. doi: 10.2337/dc14-0218. Epub

2014 Jun 19. PMID: 24947792.

66. Farahmand MA, Daneshzad E, Fung TT, Zahidi F, Muhammadi M, Bellissimo N,

Azadbakht L. What is the impact of vitamin D supplementation on glycemic control in

people with type-2 diabetes: a systematic review and meta-analysis of randomized

controlled trails. BMC Endocr Disord. 2023 Jan 16;23(1):15. doi: 10.1186/s12902-022-

01209-x. PMID: 36647067; PMCID: PMC9841647.

67. Park SJ, Park YJ, Chang J, Choi S, Lee G, Son JS, Kim KH, Oh YH, Park SM.

Association between antibiotics use and diabetes incidence in a nationally representative

retrospective cohort among Koreans. Sci Rep. 2021 Nov 4;11(1):21681. doi:

10.1038/s41598-021-01125-5. PMID: 34737360; PMCID: PMC8568925.